The treatment of non-specific urethritis (NSU) continues to challenge venereologists despite long experience with the disease. After two decades the tetracyclines remain the most effective therapeutic measure (King, 1973) , in the form of 5, 10, or 21-day courses (Parker, 1972; Carroll, 1973; John, 1971 ). The present study was designed to investigate the efficacy of two currently available tetracycline preparations in the treatment of NSU, using a twice-daily treatment regime. Oxytetracycline, in a dosage of 500 mg. twice daily, is routinely used at this clinic in the treatment of NSU, as it is known that a twicedaily dosage greatly increases the likelihood that patients will take the complete course of medication.
Material and method
The group studied consisted of 259 men who attended the clinic with NSU between September and December, 1973; these patients were enrolled into the clinical trial, the only element of selection being that they had not been treated for NSU in the preceeding 3 months. The diagnosis of NSU was made, in each case, by the exclusion of gonorrhoea and trichomoniasis after examination of urethral discharge by a Gram-stained smear, a wet preparation, and a culture for both organisms.
The treatment consisted of a double-blind administration of either encapsulated oxytetracycline (Imperacin-I.C.I.) or encapsulated tetracycline hydrochloride (Tetrabid-Organon), the latter preparation being a sustainedrelease formation designed specifically for twice-daily administration (Pines, Khaja, Greenfield, Raafat, Sreedharan, and Linsell, 1972 Using this scheme, all patients were able to follow a regime of two capsules statim followed by one capsule every 12 hrs for a total of 5 days' treatment.
Instructions for taking the capsules were given by the physician when the medication was dispensed and was also written on the containers. Each patient was asked to avoid milk and milk products around the time of taking the capsules and was advised to refrain from sexual activity and the consumption of alcohol during treatment.
All data concerning the diagnosis, signs and symptoms, trial number, etc., were recorded on special forms.
At each subsequent follow-up examination the routine was similar to that at diagnosis. Patients were asked to hold their urine for at least 3 hrs before attending for follow-up and urethral smears and cultures were taken at all examinations irrespective of the presence or absence of obvious discharge. A successful response to treatment was defined as absence of urethral discharge together with a clear urine at 7 days and again at 28 days after starting treatment. When a patient returned for follow-up examination with a recurrence of signs, with or without symptoms (recurrence being taken to mean either relapse or reinfection) he was re-treated with a further 5 days' course of the same tetracycline as he received initially. This was achieved without breaking the double-blind code. In such cases the patient was asked to return for follow-up examination 7 days later.
Results and discussion
In the Tetrabid-Organon treatment group the men ranged in age from 18 to 66 yrs (mean 26); 32 were married, and 98 were single, separated, divorced, or widowered. 59 had a past history of NSU. The incubation period was less than 10 days in 79, 10 or more days in 35, and of doubtful or unknown duration in sixteen.
In the oxytetracycline treatment group the age range was 18 to 60 yrs (mean 27); 35 were married and 94 were single, separated, divorced, or widowered. 48 had a past history of NSU. The incubation period was less than 10 days in 68, 10 or more days in 44, and of doubtful or unknown duration in seventeen.
Of the 259 men who were seen for diagnosis, 233 returned for at least one follow-up examination (Figure) . Of the 26 patients who failed to return, thirteen had received oxytetracycline and thirteen had received Tetrabid-Organon medication. Since these patients defaulted in equal numbers irrespective of the medication received, it is felt reasonable to analyse, in greater detail, data from those patient in whom follow-up was possible as a basis for a comparison of the two forms of tetracycline therapy.
The Figure illustrates the extent to which patients receiving one of the two forms of tetracycline returned for follow-up examination and highlights the increase in default rate with time. Inevitably, some patients were seen at intervals other than 7 and 28 days after initial diagnosis but such cases are allowed for in the Figure. ( The percentages of patients successfully treated were very similar with the two preparations at the first follow-up examination within 10 days (Table I) . Sixteen patients who returned required retreatment because of a recurrence of signs, with or without symptoms; eight of these patients had received oxytetracycline treatment and eight had received Tetrabid-Organon. When the sixteen retreated patients were followed-up further, thirteen returned free of signs and symptoms within the ensuing 10-day period after re-treatment and three failed to return to the clinic again.
Additionally, seven patients returned to the clinic with signs and symptoms between 10 and 14 days after treatment; all had been treated initially with oxytetracycline. They were re-treated with the same preparation. Five returned 7 days later free of signs and symptoms and two required a third course of treatment.
When the findings at 28 days after the initial diagnosis are analysed, (excluding 23 patients retreated within the first 14 days), it is found that 127 returned to the clinic (Table II) (Table II) . These figures suggest that sexual activity and alcohol may have had some influence on the re-treatment rate in the oxytetracycline-treated group, but the influence of the factors appears insufficient to account for the marked difference in the re-treatment rates observed in the two groups. Almost all patients with NSU continueto work andareunlikelytotakedrugsregularly during the day, so that a twice-daily dosage is usually taken more regularly by such patients than a regime requiring more frequent dosage.
The results of this trial suggest that TetrabidOrganon, a preparation designed specifically for twice-daily dosage is more effective than oxytetracycline given in the same manner.
Provision was made in the clinical trial to record patients' side-effects should they occur during the treatment period. Throughout the whole study the only complaints registered were two cases of slight nausea. In both cases the patients had received oxytetracycline. In a field such as venereology, the twice-daily administration ofmedication offers distinct advantages over a four-times-daily regime. This study suggests that Tetrabid-Organon, a tetracycline designed specifically for twice-daily dosage, is more effective than standard oxytetracycline, given twice daily, in the treatment of NSU.
Summary
It was satisfying to find that the traditional advice concerning abstention from sexual activity and alcohol consumption during the treatment of NSU has a sound basis. The study showed a close correlation between recurrence of NSU and failure to follow such advice. It would be interesting to investigate the means by which alcohol consumption may act to delay recovery.
